Intervention
Olaparib
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 130 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownPhase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast CancerNCT07652242 · 2026-07-14
RECRUITINGCirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian CancerNCT06856499 · 2025-12-08
RECRUITINGA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)NCT06966700 · 2025-06-30
RECRUITINGStudy of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)NCT06797635 · 2025-03-20
RECRUITINGEvaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast CancerNCT06201234 · 2024-12-13
RECRUITINGPhase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast CancerNCT06488378 · 2024-08-13
RECRUITINGStudy of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid TumorsNCT06545942 · 2024-08-13
RECRUITINGNovel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast CancerNCT05485766 · 2024-07-16
RECRUITINGEstradiol Plus Olaparib for Breast Cancer (PHOEBE)NCT05900895 · 2024-07-15
RECRUITINGSubstudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)NCT06353386 · 2024-05-20
RECRUITINGPET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBCNCT06245889 · 2024-05-01
RECRUITINGSafety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLCNCT06217757 · 2024-04-18
RECRUITINGA Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid TumorsNCT05932862 · 2024-04-03
RECRUITINGDose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXdNCT06298084 · 2024-03-21
RECRUITINGPembro With Radiation With or Without OlaparibNCT05568550 · 2023-07-27
RECRUITINGStudy of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)NCT05898399 · 2023-06-30
RECRUITINGGenomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)NCT05332561 · 2023-06-29
RECRUITINGTargeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07
RECRUITINGClinical Outcomes of Use of Olaparib in Castration Resistant Prostate CancerNCT06783127 · 2023-01-01
RECRUITINGEvaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 InhibitorNCT05536128 · 2022-12-31
RECRUITINGA Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast CancerNCT04683679 · 2021-04-21
RECRUITINGOlaparib in Patients With HRD Malignant MesotheliomaNCT04515836 · 2021-02-19
RECRUITINGOlaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast CancerNCT04090567 · 2020-07-28
RECRUITINGPHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerNCT03740893 · 2019-10-15
RECRUITINGCarboplatin or Olaparib for BRcA Deficient Prostate CancerNCT04038502 · 2019-10-01
RECRUITINGPlatinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast CancerNCT03150576 · 2016-05-01
RECRUITINGA Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate CancerNCT07641855 · 2026-09-01
NOT_YET_RECRUITINGOlaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast CancerNCT05522491 · 2026-09-01
NOT_YET_RECRUITINGTemozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)NCT05128734 · 2026-04-01
NOT_YET_RECRUITINGFPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT06909825 · 2025-02-26
ACTIVE_NOT_RECRUITINGMaintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)NCT06419179 · 2024-10-09
ENROLLING_BY_INVITATIONOPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older AdultsNCT05949424 · 2024-05-01
UNKNOWNTesting the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA MutationsNCT05807126 · 2024-03-05
WITHDRAWNPhase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung CancersNCT06130254 · 2024-01-30
TERMINATEDStudy to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid TumorsNCT06065059 · 2023-12-08
TERMINATEDA Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerNCT06112379 · 2023-11-14
ACTIVE_NOT_RECRUITINGOlaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment TrialNCT05967286 · 2023-10-23
WITHDRAWNPhase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate CancerNCT05501548 · 2023-06-30
TERMINATEDStudy of LP-184 in Patients With Advanced Solid TumorsNCT05933265 · 2023-06-09
ACTIVE_NOT_RECRUITINGStudy to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid TumorsNCT05700669 · 2023-02-20
COMPLETEDOlaparib Maintenance Therapy in Metastatic Breast CancerNCT05629429 · 2023-02-07
UNKNOWNStudy of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene AlterationsNCT05498272 · 2023-02-01
ACTIVE_NOT_RECRUITINGSMMART Adaptive Clinical Treatment (ACT) TrialNCT05238831 · 2023-01-30
WITHDRAWNOlaparib for the Treatment of Castration Resistant Prostate AdenocarcinomaNCT04951492 · 2022-11-09
TERMINATEDInduction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC PatientsNCT05174832 · 2022-09-07
UNKNOWNStudy of INCB123667 in Subjects With Advanced Solid TumorsNCT05238922 · 2022-07-05
ACTIVE_NOT_RECRUITINGNUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid TumorsNCT05252390 · 2022-03-29
TERMINATEDPredicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.NCT05340413 · 2022-03-25
COMPLETEDStudy of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain MetastasesNCT04711824 · 2022-03-09
ACTIVE_NOT_RECRUITINGA Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast CancerNCT05203445 · 2022-01-31
ACTIVE_NOT_RECRUITINGThe Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene MutationNCT05262608 · 2021-12-07
UNKNOWNOlaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine TumorsNCT04538378 · 2021-07-07
TERMINATEDFocal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)NCT04748042 · 2021-05-28
ACTIVE_NOT_RECRUITINGDurvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen LoadNCT04336943 · 2021-04-13
TERMINATEDOlaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO TrialNCT04728230 · 2021-01-05
ACTIVE_NOT_RECRUITINGHOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast CancerNCT03685331 · 2020-10-15
COMPLETEDPLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT04556617 · 2020-09-21
TERMINATEDRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With OlaparibNCT04421963 · 2020-08-04
ACTIVE_NOT_RECRUITINGStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)NCT04380636 · 2020-07-06
ACTIVE_NOT_RECRUITINGProspective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast CancerNCT04330040 · 2020-05-25
COMPLETEDCommon conditions
Breast Cancer22Prostate Cancer13Anatomic Stage IV Breast Cancer AJCC v89Metastatic Breast Cancer8Ovarian Cancer8Metastatic Castration-Resistant Prostate Cancer7Advanced Malignant Solid Neoplasm6Advanced Solid Tumor6BRCA1 Mutation6Breast Neoplasms6Castration-Resistant Prostate Carcinoma6Triple Negative Breast Cancer6Advanced Breast Cancer5Anatomic Stage III Breast Cancer AJCC v85BRCA2 Mutation5Metastatic Malignant Solid Neoplasm5Triple-Negative Breast Carcinoma5Recurrent Breast Carcinoma4Triple Negative Breast Neoplasms4Breast Cancer Metastatic3Fallopian Tube Cancer3HER2/Neu Negative3Metastatic Breast Carcinoma3Metastatic Solid Tumor3Metastatic Triple-Negative Breast Carcinoma3
Leading sponsors
National Cancer Institute (NCI)
16
AstraZeneca
14
Merck Sharp & Dohme LLC
9
M.D. Anderson Cancer Center
7
University of Washington
4
Institute of Cancer Research, United Kingdom
3
Memorial Sloan Kettering Cancer Center
3
OHSU Knight Cancer Institute
3
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
3
UNICANCER
3
Cambridge University Hospitals NHS Foundation Trust
2
Dana-Farber Cancer Institute
2
Gustave Roussy, Cancer Campus, Grand Paris
2
Laval University
2
Samsung Medical Center
2
Trial status mix
ACTIVE_NOT_RECRUITING36
COMPLETED31
RECRUITING26
TERMINATED21
UNKNOWN9
NOT_YET_RECRUITING3
WITHDRAWN3
ENROLLING_BY_INVITATION1
Phase mix
PHASE285
PHASE147
PHASE313
EARLY_PHASE12
PHASE42
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.